Clinical trials: Depression Acute
Depression, Cystic Fibrosis
Pilot Trial of Phototherapy for Acute Depression in Hospitalized Cystic Fibrosis Patients
The purpose of this study is to determine whether bright light phototherapy can improve depressive symptoms in hospitalized patients with cystic fibrosis (CF) with subsequent effects on quality of life and illness recovery.
- Trial name
- PHOTO (NCT01822197)
- Testing
- Phototherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Nationwide Children's Hospital
Bipolar Disorder, Bipolar Depression
Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy
Prospective, open-label, controlled (active comparator), randomized study of 8 weeks follow-up for the evaluation of the efficacy of extended release quetiapine (quetiapine XR) versus Sertraline in addition to previous mood…
- Trial name
- NCT00857584
- Testing
- Extended release quetiapine (quetiapine XR), Sertraline, adequate mood stabilizer
- Where
- 4 sites in Spain
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01153009
- Testing
- Vortioxetine, Duloxetine
- Where
- 56 sites in United States
- Volunteers
- 614 people
- Sponsor
- Takeda
Acute Pain
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial)
This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design.
- Trial name
- ADOPT PGx (NCT05966129)
- Testing
- Pharmacogenetic testing, Clinical decisions support
- Where
- 11 sites in United States
- Volunteers
- 1,602 people
- Sponsor
- Duke University
Acute Coronary Syndrome, Depression
MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms
Brief Summary: The aim of this study is to explore the initial feasibility and acceptability of (a) Mindfulness-Based Cognitive Therapy (MBCT) adapted for ACS patients; (b) the group videoconferencing delivery medium; and (c)…
- Conditions
- Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina
- Trial name
- NCT04231097
- Testing
- MBCT intervention for ACS patients
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Depression
Treatment of Depression in Acute Coronary Syndrome (ACS) Patients
Emotional states of depression in association with ischemic heart diseases, such as myocardial infarction or unstable angina, are risk factors for subsequent cardiac events and mortality.
- Trial name
- TREATED-ACS (NCT00998400)
- Testing
- CBT in combination with WBT and life style modification
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Bologna
Bipolar Depression, Suicidal Ideas
Sequential Therapy for the Treatment of Severe Bipolar Depression.
NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or…
- Conditions
- Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
- Trial name
- STABIL-B (NCT02974010)
- Testing
- NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- NeuroRx, Inc.
Major Depressive Disorder
Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
The purpose of this Venlafaxine-referenced study is to evaluate the efficacy, safety and tolerability of two fixed doses of Vortioxetine in the acute treatment of Major Depressive Disorder (MDD).
- Trial name
- NCT00839423
- Testing
- Vortioxetine (Lu AA21004), Venlafaxine XL
- Volunteers
- 426 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00672620
- Testing
- Vortioxetine, Duloxetine
- Where
- 38 sites in United States
- Volunteers
- 611 people
- Sponsor
- Takeda
Bipolar Disorder, Depression
Acute Psychotherapy for Bipolar II Depression
This proposed study is designed to compare the efficacy of interpersonal and social rhythm therapy (IPSRT) alone to IPSRT plus medication as an acute treatment for bipolar II depression.
- Trial name
- NCT01133821
- Testing
- IPSRT plus quetiapine
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Holly Swartz
Depressive Disorder, Major
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01179516
- Testing
- Vortioxetine
- Where
- 61 sites in United States
- Volunteers
- 469 people
- Sponsor
- Takeda
Depression, Suicide
Ketamine for Depression and Suicide Risk
The purpose of this research study was to find out if the medication known as ketamine could help the symptoms of depression. This drug is approved by the U.S.
- Trial name
- Ketamine (NCT02094898)
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Acute Coronary Syndrome, Depression
Healthy Heart Habits
Approximately 350,000 Acute Coronary Syndrome (ACS) patients experience significant depression symptoms each year in the US. Post-ACS depressed mood interferes with patients making necessary changes to behavioral risk factors…
- Trial name
- H^3 (NCT04158219)
- Testing
- Behavioral activation for health and depression (BA-HD)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Hennepin Healthcare Research Institute
Bipolar Depression
Ceftriaxone in the Management of Bipolar Depression
We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to…
- Trial name
- NCT00566111
- Testing
- ceftriaxone, Saline solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Respiratory Insufficiency, Depression
Behavioral Activation-Rehabilitation to Improve Depressive Symptoms & Physical Function After Acute Respiratory Failure
More and more people are surviving after receiving life support for respiratory failure in the intensive care unit, but these patients often experience problems with depression and physical functioning that lead to reduced…
- Conditions
- Respiratory Insufficiency, Depression, Rehabilitation, Critical Care
- Trial name
- BEHAB (NCT03431493)
- Testing
- Behavioral Activation - Rehabilitation
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Johns Hopkins University
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate the efficacy, tolerability and the safety of two fixed doses of vortioxetine in the treatment of major depressive disorder.
- Trial name
- NCT01140906
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 607 people
- Sponsor
- H. Lundbeck A/S
Anti-Psychotic, Management of Manifestations of Psychotic Disorders
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Cycle Pharmaceuticals Ltd. (Cycle) is developing an oral tablet formulation of Chlorpromazine Hydrochloride and intends to conduct bioequivalence trials to demonstrate its similarity to the RLD.
- Conditions
- Anti-Psychotic, Management of Manifestations of Psychotic Disorders, Treatment of Schizophrenia, Control Nausea and Vomiting
- Trial name
- NCT02943213
- Testing
- Chlorpromazine Hydrochloride
- Where
- South Africa
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cycle Pharmaceuticals Ltd.
Cardiovascular Diseases, Acute Coronary Syndrome
MBCT Via Group Videoconferencing for Acute Coronary Syndrome Patients With Depressive Symptoms: A Pilot RCT
The aim of this study is to establish, in a pilot RCT (approx. N=50 participants) with a time- and attention-matched health enhancement control, (a) the feasibility of the recruitment procedures (screening, eligibility…
- Conditions
- Cardiovascular Diseases, Acute Coronary Syndrome, Depression
- Trial name
- NCT04799899
- Testing
- Adapted MBCT, Cardiac Health Enhancement
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients
To assess the efficacy of Vortioxetine (5 mg daily) versus placebo in the acute treatment of depression by means of the change from baseline in the 24-item Hamilton Depression Scale (HAM-D24) total score after 8 weeks of…
- Trial name
- NCT00811252
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
Acute Bipolar Depression
Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression
The purpose of this study is to compare the efficacy of quetiapine fumarate monotherapy with quetiapine fumarate in combination with lithium in the treatment of a major depressive episode in patients with bipolar disorder.
- Trial name
- QUALITY (NCT00883493)
- Testing
- Quetiapine fumarate XR, Lithium carbonate
- Where
- 24 sites in Argentina, Brazil and 7 more
- Volunteers
- 421 people
- Sponsor
- AstraZeneca